Cargando…
Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity
Retigabine is unique among anticonvulsant drugs by targeting the neuronal M-channel, which is composed of K(V)7.2/K(V)7.3 and contributes to the negative neuronal resting membrane potential. Unfortunately, retigabine causes adverse effects, which limits its clinical use. Adverse effects may be reduc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398146/ https://www.ncbi.nlm.nih.gov/pubmed/32365171 http://dx.doi.org/10.1085/jgp.202012576 |
_version_ | 1783565905495588864 |
---|---|
author | Larsson, Johan E. Karlsson, Urban Wu, Xiongyu Liin, Sara I. |
author_facet | Larsson, Johan E. Karlsson, Urban Wu, Xiongyu Liin, Sara I. |
author_sort | Larsson, Johan E. |
collection | PubMed |
description | Retigabine is unique among anticonvulsant drugs by targeting the neuronal M-channel, which is composed of K(V)7.2/K(V)7.3 and contributes to the negative neuronal resting membrane potential. Unfortunately, retigabine causes adverse effects, which limits its clinical use. Adverse effects may be reduced by developing M-channel activators with improved K(V)7 subtype selectivity. The aim of this study was to evaluate the prospect of endocannabinoids as M-channel activators, either in isolation or combined with retigabine. Human K(V)7 channels were expressed in Xenopus laevis oocytes. The effect of extracellular application of compounds with different properties was studied using two-electrode voltage clamp electrophysiology. Site-directed mutagenesis was used to construct channels with mutated residues to aid in the mechanistic understanding of these effects. We find that arachidonoyl-L-serine (ARA-S), a weak endocannabinoid, potently activates the human M-channel expressed in Xenopus oocytes. Importantly, we show that ARA-S activates the M-channel via a different mechanism and displays a different K(V)7 subtype selectivity compared with retigabine. We demonstrate that coapplication of ARA-S and retigabine at low concentrations retains the effect on the M-channel while limiting effects on other K(V)7 subtypes. Our findings suggest that improved K(V)7 subtype selectivity of M-channel activators can be achieved through strategically combining compounds with different subtype selectivity. |
format | Online Article Text |
id | pubmed-7398146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-73981462021-02-03 Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity Larsson, Johan E. Karlsson, Urban Wu, Xiongyu Liin, Sara I. J Gen Physiol Article Retigabine is unique among anticonvulsant drugs by targeting the neuronal M-channel, which is composed of K(V)7.2/K(V)7.3 and contributes to the negative neuronal resting membrane potential. Unfortunately, retigabine causes adverse effects, which limits its clinical use. Adverse effects may be reduced by developing M-channel activators with improved K(V)7 subtype selectivity. The aim of this study was to evaluate the prospect of endocannabinoids as M-channel activators, either in isolation or combined with retigabine. Human K(V)7 channels were expressed in Xenopus laevis oocytes. The effect of extracellular application of compounds with different properties was studied using two-electrode voltage clamp electrophysiology. Site-directed mutagenesis was used to construct channels with mutated residues to aid in the mechanistic understanding of these effects. We find that arachidonoyl-L-serine (ARA-S), a weak endocannabinoid, potently activates the human M-channel expressed in Xenopus oocytes. Importantly, we show that ARA-S activates the M-channel via a different mechanism and displays a different K(V)7 subtype selectivity compared with retigabine. We demonstrate that coapplication of ARA-S and retigabine at low concentrations retains the effect on the M-channel while limiting effects on other K(V)7 subtypes. Our findings suggest that improved K(V)7 subtype selectivity of M-channel activators can be achieved through strategically combining compounds with different subtype selectivity. Rockefeller University Press 2020-05-04 /pmc/articles/PMC7398146/ /pubmed/32365171 http://dx.doi.org/10.1085/jgp.202012576 Text en © 2020 Larsson et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Larsson, Johan E. Karlsson, Urban Wu, Xiongyu Liin, Sara I. Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity |
title | Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity |
title_full | Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity |
title_fullStr | Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity |
title_full_unstemmed | Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity |
title_short | Combining endocannabinoids with retigabine for enhanced M-channel effect and improved K(V)7 subtype selectivity |
title_sort | combining endocannabinoids with retigabine for enhanced m-channel effect and improved k(v)7 subtype selectivity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398146/ https://www.ncbi.nlm.nih.gov/pubmed/32365171 http://dx.doi.org/10.1085/jgp.202012576 |
work_keys_str_mv | AT larssonjohane combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity AT karlssonurban combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity AT wuxiongyu combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity AT liinsarai combiningendocannabinoidswithretigabineforenhancedmchanneleffectandimprovedkv7subtypeselectivity |